Evaluating Cardiometabolic Drivers, Racial Disparities, and Projections in U.S. Heart Failure

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Journal of Cardiac Failure https://doi.org/10.1016/j.cardfail.2026.07.009
Dr. Eiran Z. Gorodeski et al.

Points

Heart Failure Society of America researchers published a comprehensive report demonstrating a thirty seven percent increase in United States heart failure mortality between 2010 and 2023.
Epidemiological tracking revealed that heart failure mortality surged by one hundred twenty one percent in adults aged twenty five to forty four and ninety six percent in middle aged adults.
Population data indicated that nearly one in four Americans will develop heart failure during their lifetime with one third currently meeting Stage A at risk criteria.
Disparity analysis established that Black Americans experience heart failure at more than triple the rate of Asian Americans and double the rate of white populations across high risk Southern states.
Authors concluded that accelerating cardiometabolic comorbidities including obesity and hypertension will increase national heart failure costs from three hundred twelve billion to eight hundred fifty eight billion dollars by 2050.

Summary

This epidemiological report evaluated the national burden, demographic trajectories, and financial projections of heart failure (HF) in the United States. Published in the Journal of Cardiac Failure by the Heart Failure Society of America (HFSA), the comprehensive update analyzed population-level mortality trends between 2010 and 2023. Given that overall HF mortality increased by 37% during this period, reversing more than a decade of prior clinical progress, the report sought to quantify disease staging, subtype distribution, and racial and geographic disparities driving this accelerating public health crisis.

Epidemiological staging indicates that 33% of asymptomatic U.S. adults meet criteria for Stage A at-risk HF, while 24% to 34% exhibit Stage B pre-HF, culminating in an estimated lifetime HF risk of 24% (1 in 4 individuals). Overall HF mortality doubled among younger demographics: deaths surged by 121% among adults aged 25 to 44 between 2010 and 2020, increased by 96% in adults aged 45 to 64, and rose by 23% among seniors aged 65 and older. Comorbid cardiometabolic drivers were highly prevalent, with 33% of HF patients presenting with hypertension, 33% with obesity, and 40% with diabetes. Black Americans exhibited the highest disease burden, with HF rates exceeding triple those of Asian Americans and double those of white individuals. Regionally, mortality clustered heavily in Mississippi, Oklahoma, Alabama, and Arkansas. Driven by rising rates of hypertension and obesity, the lifetime risk of HF with preserved ejection fraction (HFpEF) is projected to eclipse HF with reduced ejection fraction (HFrEF), with women demonstrating a disproportionately higher lifetime HFpEF risk.

The authors conclude that rising cardiometabolic comorbidity rates are driving a dramatic surge in premature HF mortality among young and middle-aged adults. Total economic costs are projected to escalate from $312 billion to $858 billion by 2050. These epidemiological findings highlight an urgent need for early Stage A and B screening, aggressive cardiometabolic risk factor control, and equitable dissemination of guideline-directed medical therapies to mitigate the burgeoning public health and economic burden.

Link to the article: https://onlinejcf.com/article/S1071-9164(26)00406-9/fulltext

References

Gorodeski, E. Z., Fonarow, G. C., Goyal, P., Ahmad, F. S., Albert, N. M., Bloom, M., Bozkurt, B., Breathett, K., Carter, S. J., Cheng, R. K., Chuzi, S., Clarkson, S. A., Cowger, J. A., DeFilippis, E. M., Denfeld, Q. E., Deswal, A., Drazner, M. H., Dunlay, S. M., Echols, M. R., … Ziaeian, B. (2026). Hf stats 2026: An updated report on heart failure epidemiology and outcomes from the heart failure society of america. Journal of Cardiac Failure, S1071916426004069. https://doi.org/10.1016/j.cardfail.2026.07.009